peer reviewedThe diabetic patient, when type 2 diabetes is newly diagnosed, raises a therapeutic problem commonly observed in clinical practice, which is more complex than expected at first glance. The physician has to select the most appropriate antidiabetic oral agent as first choice, to consider the potential of using combined glucose-lowering therapies, to fix glycaemic target taking into account the individual benefit/risk ratio, and to offer the best protection against cardiovascular complications. The present clinical case illustrates such therapeutic problem describing a patient with a high cardiovascular risk profile who experienced a hypoglycaemic episode after the prescription of glibenclamide following the discovery of a moderat...
peer reviewedPROactive is a prospective, randomised controlled trial in 5238 patients with type 2 di...
peer reviewedADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical t...
peer reviewedExenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors o...
peer reviewedThe diabetic patient, when type 2 diabetes is newly diagnosed, raises a therapeutic pro...
peer reviewedAlthough strict glucose control can prevent or delay the onset of complications in pati...
peer reviewedType 2 diabetes is frequently associated with other comorbidities among which abdominal...
peer reviewedAs compared to type 1 diabetes, type 2 diabetes usually requires insulin at a late stag...
peer reviewedIt is estimated that 80% of individuals with type 2 diabetes die of cardiovascular dise...
peer reviewedType 2 diabetes (T2D) is a complex disease characterized by different pathophysiologica...
peer reviewedEven if type 2 diabetes is a complex disease combining hyperglycaemia and various other...
peer reviewedHeart failure is raising an increasing interest in patients with type 2 diabetes. Indee...
peer reviewedType 2 diabetes is a complex disease characterized by a dual defect of insulin secretio...
peer reviewedOwing to the epidemics of type 2 diabetes, it is important to develop strategies of pre...
peer reviewedL'hypertension artérielle est fréquemment observée chez le patient diabétique de type 2...
peer reviewedGlucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 5...
peer reviewedPROactive is a prospective, randomised controlled trial in 5238 patients with type 2 di...
peer reviewedADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical t...
peer reviewedExenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors o...
peer reviewedThe diabetic patient, when type 2 diabetes is newly diagnosed, raises a therapeutic pro...
peer reviewedAlthough strict glucose control can prevent or delay the onset of complications in pati...
peer reviewedType 2 diabetes is frequently associated with other comorbidities among which abdominal...
peer reviewedAs compared to type 1 diabetes, type 2 diabetes usually requires insulin at a late stag...
peer reviewedIt is estimated that 80% of individuals with type 2 diabetes die of cardiovascular dise...
peer reviewedType 2 diabetes (T2D) is a complex disease characterized by different pathophysiologica...
peer reviewedEven if type 2 diabetes is a complex disease combining hyperglycaemia and various other...
peer reviewedHeart failure is raising an increasing interest in patients with type 2 diabetes. Indee...
peer reviewedType 2 diabetes is a complex disease characterized by a dual defect of insulin secretio...
peer reviewedOwing to the epidemics of type 2 diabetes, it is important to develop strategies of pre...
peer reviewedL'hypertension artérielle est fréquemment observée chez le patient diabétique de type 2...
peer reviewedGlucovance, recently launched by Merck-Lipha (Glucovance 500 mg/2.5 mg and Glucovance 5...
peer reviewedPROactive is a prospective, randomised controlled trial in 5238 patients with type 2 di...
peer reviewedADOPT ("A Diabetes Outcome Progression Trial") is a double-blind, controlled clinical t...
peer reviewedExenatide (Byetta) is a synthetic derivative of exendin-4 and an agonist of receptors o...